Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Unrecognized Distal Biceps Rupture Associated with Brachial Plexus Injury
Strother, Courtney R. Carlson, Crowe, Christopher S. , Lee, Ellen Y. , Zelenski, Nicole A. , Bishop, Allen T. , Spinner, Robert J. , Shin, Alexander Y. , Carlson Strother, Courtney R, Shin, Alexander Y , Bishop, Allen T , Zelenski, Nicole A.

JBJS Case Connector | July 17, 2025 | Volume: 15 | Issue: 3 | Pages: No page available

10.2106/jbjs.cc.24.00451 | PMID 40674459 Get It

Case: An upper trunk brachial plexus injury patient underwent ulnar motor fascicular to biceps motor nerve transfer. At 6 months postoperative, the patient had trace biceps firing but was diagnosed with an unrecognized rupture of the distal biceps tendon, requiring reconstruction. Another patient with C5-T1 injury was noted to have distal biceps tendon rupture at the time of gracilis muscle transfer. Both patients had gravity-assisted elbow flexion at 1-year follow-up. Conclusion: Biceps rupture is an uncommon concomitant injury with brachial plexus trauma and challenging to diagnose in the context of a paretic limb. Thorough history and intraoperative biceps tendon palpation will ensure these injuries are identified.
ASHP Guidelines on the Evaluation of Off-Label Medication Use in the Inpatient Setting
Durant, Karin M , Gwin, Julie, Leber, Molly Billstein , Mathew, Nisha, Matonti, Lisa, Segovia, Margaret F, Williams, Cicely, Segovia, Margaret F

American Journal of Health-System Pharmacy | July 17, 2025 | Volume: 82 | Issue: 23 | Pages: e1013-e1019

10.1093/ajhp/zxaf166 | PMID 40674242 Get It

Secondary blastoid plasma cell leukemia: can an old dog learn new tricks?
Zhou, Jiehao , Cheng, Jinjun

Blood | July 17, 2025 | Volume: 146 | Issue: 3 | Pages: 396-396

10.1182/blood.2025029282 | PMID 40674113 Get It

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Borgeaud, Maxime , Olivier, Timothée , Bar, Jair , Saw, Stephanie P.L. , Parikh, Kaushal , Banna, Giuseppe Luigi , Vito, Claudio De , Feldman, Jill , Le, Xiuning , Addeo, Alfredo , Saw, Stephanie Pei Li , De Vito, Claudio , Addeo, Alfredo , Olivier, Timothée , Feldman, Jill

CA: A Cancer Journal for Clinicians | July 17, 2025 | Volume: 75 | Issue: 5 | Pages: 387-409

10.3322/caac.70024 | PMID 40673977 Get It

AbstractThe discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments. Recent advancements have significantly reshaped the treatment paradigm for EGFR‐mutant non‐small cell lung cancer. TKIs are now incorporated into the management of early stage and locally advanced disease, and phase 3 trials have explored combination strategies in metastatic settings. Although these intensified approaches improve progression‐free survival, they come with increased toxicity and higher costs, underscoring the need for precise patient selection to maximize benefit. Emerging data on biomarkers, such as co‐mutations and circulating tumor DNA, show promise for refining treatment decisions. In addition, significant progress in understanding resistance mechanisms to EGFR TKIs has broadened therapeutic options. This review provides a comprehensive overview of the current landscape of EGFR‐mutant nonsmall cell lung cancer, highlighting recent breakthroughs and discussing strategies to optimize treatment based on the latest evidence.
Apolipoprotein A-I Infusions in Coronary Artery Disease: A Systematic Review
Ahmad, Rimsha , Hussain, Syed Sadam, Niaz, Mahnoor, Frishman, William H. , Aronow, Wilbert S., Khan, Saifullah , Kumar, Mahesh , Aronow, Wilbert S.

Cardiology in Review | July 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001002 | PMID 40673933 Get It

Coronary artery disease (CAD) is the leading cause of death globally. Apolipoprotein A-1 (apoA-1), the primary protein component of high-density lipoprotein (HDL), facilitates reverse cholesterol transport and has emerged as a potential therapeutic target. While pharmacologic efforts to raise HDL-C levels have failed to reduce cardiovascular events, focus has shifted to HDL functionality, particularly cholesterol efflux capacity (CEC). ApoA-1 infusions have demonstrated antiatherogenic effects in preclinical models and early human trials by enhancing CEC and promoting cholesterol clearance. This review summarizes the rationale and evolving clinical trial landscape investigating apoA-1 infusions as a novel therapy for CAD prevention and treatment.
Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic
Droste, Marvin , Puhka, Maija , Ng, Monica Suet Ying , Álvarez‐Llamas, Gloria , Borràs, Francesc E. , Büscher, Anja , Bussolati, Benedetta , Dear, James W. , Hoorn, Ewout J. , Lenassi, Metka , Pink, Desmond , Tiwari, Swasti , Vizio, Dolores Di , Zarovni, Nataša , Martens‐Uzunova, Elena S. , Erdbrügger, Uta , Ng, Monica S Y , Alvarez-Llamas, Gloria , Borràs, Francesc E , Bussolati, Benedetta , Falcón-Perez, Juan Manual , Lenassi, Metka , Lucien, Fabrice , Tertel, Tobias , Martens-Uzunova, Elena S , Royen, Martin E. van , Blijdorp, Charles J. , Falcón‐Pérez, Juan Manuel , Giebel, Bernd , Grange, Cristina , Leivo, Janne , Llorente, Alicia , Lucien, Fabrice , Mertens, Inge , Mischak, Harald , Yuen, Peter S.T. , Jenster, Guido , Burger, Dylan

Journal of Extracellular Vesicles | July 17, 2025 | Volume: 14 | Issue: 7 | Pages: No page available

10.1002/jev2.70120 | PMID 40673839 Get It

ABSTRACT Despite remarkable interest in the biomarker potential of urinary extracellular vesicles (uEVs) and the identification of numerous promising candidates, their clinical translation still presents multiple challenges. The opportunities for successful translation are obvious, yet the main roadblocks on the way have hardly been systematically considered and more coordinated approaches are needed to overcome them. In the present review article, we have identified the most relevant roadblocks of clinical translation of urinary EV‐based biomarkers and discuss possible solutions to overcome them. These roadblocks are categorized as fundamental and technical but also related to development of novel biomarker assays and clinical acceptance. In addition, hurdles within the regulatory approval process are discussed. It is clear that various roadblocks to clinical translation of urinary EV biomarkers exist; however, they are addressable by promoting rigor and reproducibility as well as collaboration between basic and clinical scientists, clinicians, industry and regulatory bodies. Moreover, knowledge of obstacles for assay development and regulatory requirements should already be considered when developing a new biomarker to maximize the chance of successful translation. This review presents not only a status quo, but also a roadmap for the further development of the field.
The New Horizon: A Viewpoint of Novel Drugs, Biomarkers, Artificial Intelligence, and Self-Management in Improving Kidney Transplant Outcomes
Silva, Artur Quintiliano Bezerra da , Bentall, Andrew , Quintiliano, Artur , Bentall, Andrew

Journal of Clinical Medicine | July 17, 2025 | Volume: 14 | Issue: 14 | Pages: 5077

10.3390/jcm14145077 | PMID 40725768 Get It

The increasing prevalence of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) has led to a growing demand for kidney transplantation (KTx). Identifying risk factors that enable improved allograft survival through novel therapeutic agents, advanced biomarkers, and artificial intelligence (AI)-driven data integration are critical to addressing this challenge. Drugs, such as SGLT2 inhibitors and finerenone, have demonstrated improved outcomes in patients but lack comprehensive long-term evidence in KTx patients. The use of biomarkers, including circulating cytokines and transcriptomics, coupled with AI, could enhance early detection and personalized treatment strategies. Addressing patient self-management and addressing health access disparities may be more achievable using technologies used at home rather than traditional models of healthcare and thus lead to increased transplant success, both in terms of transplantation rates and allograft longevity.
Hypertrophic Olivary Degeneration in Brainstem Cavernous Malformations: An Analysis of Predictors and Clinical Implications
Bektas, Delal , Graepel, Stephen , Bektas, Delal , Lanzino, Giuseppe , Flemming, Kelly D.

Neurosurgery | July 17, 2025 | Volume: 98 | Issue: 2 | Pages: 384-393

10.1227/neu.0000000000003631 | PMID 40673665 Get It

BACKGROUND AND OBJECTIVES: This study aimed to evaluate predictors of hypertrophic olivary degeneration (HOD) in patients with brainstem cerebral cavernous malformations (CCMs) and to examine its association with functional outcomes. METHODS: A cohort of 120 patients with brainstem CCM was analyzed using prospectively collected registry data and retrospective chart reviews. Demographic, clinical, radiological, and surgical data were evaluated. Predictors of HOD and poor functional outcomes were identified through univariate and multivariate analyses. RESULTS: The cohort included 54 females (45.0%), with a mean age at diagnosis of 43.8 years (SD = 16.5). Symptomatic hemorrhage was present in 70.8% of patients at diagnosis, and 28.3% underwent surgical intervention. Radiographic HOD was observed in 20% of patients (n = 24), with 87% of cases involving lesions within the Guillain–Mollaret triangle (GMT). Larger lesion size (odds ratio [OR] = 1.09, 95% CI: 1.01-1.19, P = .027), pontine location (OR = 19.81, P = .006), and GMT involvement (OR = 25.24, P < .001) were significantly associated with HOD. Repeated symptomatic hemorrhage and surgery, including the extent of resection, did not predict the development of HOD. Patients with HOD had worse functional outcomes at last follow-up ( P = .012), with GMT involvement remaining the sole independent predictor of mRS ≥3 (OR = 3.44, P = .040). CONCLUSION: HOD reflects trans-synaptic degeneration within the GMT and is strongly associated with lesion location and size. It serves as a radiological marker of cumulative damage to the brainstem. Preoperative imaging and risk stratification focusing on GMT involvement are critical for guiding management and counseling patients with brainstem CCM.
Disproportionate Left Ventricular Enlargement in Mitral Valve Prolapse: Prevalence, Predictors, and Association With Outcomes
Topilsky, Yan , Essayagh, Benjamin , Benfari, Giovanni , Tourneau, Thierry Le , Antoine, Clémence , Grigioni, Francesco , Roussel, Jean‐Christian , Bax, Jeroen J. , Wijngaarden, Aniek L. van , Tribouilloy, Christophe , Loewenstein, Itamar , Thapa, Prabin , Le Tourneau, Thierry , Marsan, Nina Ajmone , van Wijngaarden, Aniek , Tribouilloy, Christophe , Hochstadt, Aviram , Thapa, Prabin , Michelena, Hector I , Enriquez-Sarano, Maurice , Bax, Jeroen J , Benfari, Giovanni , Essayagh, Benjamin , Grigioni, Francesco , Marsan, Nina Ajmone , Michelena, Héctor I. , Enriquez‐Sarano, Maurice

Journal of the American Heart Association | July 17, 2025 | Volume: 14 | Issue: 15 | Pages: No page available

10.1161/jaha.124.040868 | PMID 40673524 Get It

Background Left ventricular (LV) end‐systolic enlargement in severe degenerative mitral‐regurgitation (MR) is a class I surgical trigger. Whether it occurs disproportionately to less‐than‐severe MR due to mitral valve prolapse and is associated with mortality are unknown. We aimed to analyze prevalence and association with survival of disproportionate LV enlargement in less‐than‐severe MR. Methods A multicenter cohort international study enrolled 2848 consecutive patients (52% women, 69±16 years) with degenerative MR prospectively quantified and graded mild or moderate. Primary end point was survival under medical management. Secondary outcome was survival throughout follow‐up stratified by performance of early mitral surgery within 3 months postdiagnosis. Results Among LV remodeling parameters (abnormal end‐diastolic diameter, LV end‐systolic diameter [LVESD] absolute and indexed), LVESD ≥40 mm (present in 12.4%) was the sole independent associate of reduced survival (5‐year 70±3 versus 76±9%; P =0.009). LVESD ≥40 mm was independently linked to larger body surface area, effective regurgitant orifice, and left atrium, and to male sex and diabetes. With multivariable comprehensive adjustment, LVESD ≥40 mm (adjusted hazard ratio [aHR], 1.25 [95% CI, 1.005–1.53]; P =0.04) remained associated with excess mortality under medical management, even after adjustment for lowered ejection fraction (aHR, 1.49 [95% CI, 1.13–1.95]; P =0.004) and in all patient subsets. Among patients with moderate degenerative MR and LVESD ≥40 mm, 22% underwent mitral surgery within 3 months, which was associated with superior survival, even after comprehensive adjustment (aHR, 0.11 [95% CI, 0.005–0.51]; P =0.002). Conclusions Disproportionate LV enlargement in patients with less‐than‐severe degenerative MR is common, particularly with larger bodies, regurgitation, and overall cardiac remodeling. LVESD ≥40 mm is associated with worse survival independent of all baseline characteristics, even lowered ejection fraction, and represents a marker for risk stratification of patients who are generally not yet considered for medical or surgical/interventional treatment.
Longitudinal Study of the Vascular Glycocalyx and Urinary Podocyte Markers During Pregnancy
Valencia, Oscar A. Garcia , Šuvakov, Sonja , Dilmaghani, Darah, Weissgerber, Tracey L. , Đokić, Vladimir , Gavrilovici, Paul, Hatamova, Jennet, Miao, Jing , Jayachandran, Muthuvel , Nath, Karl A. , Garcia-Valencia, Oscar , Tu, Haitao , Dilmaghani, Darah , Weissgerber, Tracey L , Djokic, Vladimir , Miao, Jing , White, Wendy M, Jayachandran, Muthuvel , Nath, Karl A , Garovic, Vesna D , Hatamova, Jennet , Milić, Nataša , White, Wendy M., Garovic, Vesna D.

Journal of the American Heart Association | July 17, 2025 | Volume: 14 | Issue: 15 | Pages: No page available

10.1161/jaha.124.039904 | PMID 40673523 Get It

Background We aimed to assess the longitudinal changes of glycocalyx, a proteoglycan/glycoprotein layer that lines and protects endothelial cells in normotensive pregnancies (NPs); to correlate glycocalyx parameters with kidney injury markers (podocin‐positive to nephrin‐positive [P/N] ratio); and to explore changes in P/N ratio in preeclampsia. Methods Plasma and urine samples and glycocalyx measurements using side‐stream darkfield imaging were collected at each trimester from pregnant women (n=31). Plasma glycocalyx components were measured by ELISA, and urinary P/N‐positive extracellular vesicles by flow cytometry. Results In NPs (n=26), glycocalyx degradation increased from the first to the second trimester ( P =0.008) and returned to first‐trimester values in the third trimester ( P =0.008). Microvascular perfusion decreased from the first to the second trimester ( P =0.006) and increased back to first‐trimester values by the third trimester ( P =0.039). Plasma syndecan 1 level showed a steady increase from the first to the second trimester ( P <0.001) and further in the third trimester ( P <0.001); hyaluronic acid increased from the first to the second trimester ( P =0.016) without further changes. Glycocalyx degradation was associated with an increase in P/N ratio from the first to the second trimester of NPs and remained stable through the third trimester. P/N ratio strongly correlated with elevated syndecan 1 and hyaluronic acid levels in the third trimester. Comparison of P/N ratios between NP and preeclampsia (n=5) showed higher values in preeclampsia across all trimesters ( P =0.028). Conclusions Glycocalyx changes during NPs are associated with elevated urinary podocyte markers. Increase in P/N ratio across NPs, and further in preeclampsia, suggests that podocyte injury in preeclampsia is extension of physiological changes in pregnancy, which may predate its clinical presentation.